Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents
出版年份 2021 全文链接
标题
Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents
作者
关键词
-
出版物
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 22, Pages 16573-16597
出版商
American Chemical Society (ACS)
发表日期
2021-11-17
DOI
10.1021/acs.jmedchem.1c01155
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease
- (2021) Peter Jenner et al. Expert Review of Neurotherapeutics
- Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors
- (2021) Xuewu Liang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer
- (2021) Ying-Chao Duan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
- (2020) Shipeng He et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385
- (2020) Jin-Ju Byeon et al. MOLECULES
- A 2A adenosine receptor antagonists: From caffeine to selective non‐xanthines
- (2020) Kenneth A. Jacobson et al. BRITISH JOURNAL OF PHARMACOLOGY
- Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
- (2020) Tingting Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Assessment of Pharmacokinetics and Metabolism Profiles of SCH 58261 in Rats Using Liquid Chromatography–Mass Spectrometric Method
- (2020) Yuri Park et al. MOLECULES
- Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
- (2020) Fazhi Yu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists
- (2020) Jinfeng Zhang et al. Pharmaceuticals
- Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG
- (2019) Jamie N. Anastas et al. CANCER CELL
- Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
- (2019) Yahui Huang et al. Acta Pharmaceutica Sinica B
- Subtype-Selective Fluorescent Ligands as Pharmacological Research Tools for the Human Adenosine A2A Receptor
- (2019) Eleonora Comeo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
- (2018) Robert D. Leone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A2AAdenosine Receptor Gene Deletion or Synthetic A2AAntagonist Liberate Tumor-Reactive CD8+T Cells from Tumor-Induced Immunosuppression
- (2018) Jorgen Kjaergaard et al. JOURNAL OF IMMUNOLOGY
- Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma
- (2018) Dizhong Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections
- (2018) Yahui Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer
- (2018) Heba M. Hesham et al. MEDICINAL RESEARCH REVIEWS
- Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge
- (2018) Jiyue Zheng et al. ACS Chemical Neuroscience
- Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging
- (2017) Aren van Waarde et al. MEDICINAL RESEARCH REVIEWS
- Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
- (2016) Kaiming Sun et al. MOLECULAR CANCER THERAPEUTICS
- History and Perspectives of A2AAdenosine Receptor Antagonists as Potential Therapeutic Agents
- (2015) Delia Preti et al. MEDICINAL RESEARCH REVIEWS
- Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
- (2015) Paul A. Beavis et al. Cancer Immunology Research
- Synthesis and Pharmacological Evaluation of Dual Acting Ligands Targeting the Adenosine A2A and Dopamine D2 Receptors for the Potential Treatment of Parkinson’s Disease
- (2014) Manuela Jörg et al. JOURNAL OF MEDICINAL CHEMISTRY
- Adenosine A2A Receptor as a Drug Discovery Target
- (2013) Manuel de Lera Ruiz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates
- (2013) Christopher J. Millard et al. MOLECULAR CELL
- Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions
- (2012) W. Liu et al. SCIENCE
- Adenosine A2A Receptor Antagonists and Parkinson’s Disease
- (2011) Brian C. Shook et al. ACS Chemical Neuroscience
- Second-Generation Histone Deacetylase 6 Inhibitors Enhance the Immunosuppressive Effects of Foxp3+ T-Regulatory Cells
- (2011) Jay H. Kalin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation
- (2011) Guillaume Lebon et al. NATURE
- International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors--An Update
- (2011) B. B. Fredholm et al. PHARMACOLOGICAL REVIEWS
- Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine
- (2011) Andrew S. Doré et al. STRUCTURE
- CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
- (2010) Cheng-Jung Lai et al. CANCER RESEARCH
- Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
- (2010) Xiong Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist
- (2008) V.-P. Jaakola et al. SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now